Axovant Sciences (NASDAQ: AXON) reported Q4 EPS of $0.40, $0.04 better than the analyst estimate of $0.36. Revenue for the quarter came in at $226 million versus the consensus estimate of $180.96 million.

GUIDANCE:

Axovant Sciences sees FY2021 revenue of $740-780 million, versus the consensus of $742.24 million.

For earnings history and earnings-related data on Axovant Sciences (AXON) click here.